
New Partnership for Africa’s Development (NEPAD) Agency, the Southern African Network for Biosciences (SANBIO) has submitted a study design and a report for a phase one clinical trial protocol aimed at establishing the safety of the Sondashi Formula (SF2000) formulation to Government.
Presenting the two reports to Science Permanent Secretary Sherry Thole at her office in Lusaka today, NEPAD Agency Director Luke Mumba said scientists have found the SF2000 to be useful in clinical trials for HIV/AIDS.
Prof Mumba said scientists have found the SF2000 to possess particles that can be used in clinical trials for HIV/AIDS.
He said the reports were a significant milestone in the country’s discovery of an HIV/AIDS drug.
Prof Mumba also said there was need for the world to deal with the global HIV/AIDS crisis, which was one of the greatest humanitarian challenges of this generation with the seriousness it deserved.
He said a combination of indigenous knowledge and the rich biodiversity with the application of scientific and traditional knowledge may just be the answer to the AIDS pandemic.
And speaking at the same occasion, Science PS Sherry Thole expressed hope that the SF2000 would play a critical role in the health delivery system in the near future.
Ms Thole however said that for the country to realise the goal, a lot more research work needed to be done.
She said the immediate task was for the nation to look for funds to support the clinical trials, adding that her ministry in liaison with other stakeholders like the Ministry of Health and the National AIDS Council (NAC) would work on finding ways to do this.
And inventor of the SF2000 Ludwig Sondashi said the report of the effectiveness of the SF2000 in fighting AIDS had proven his critics wrong.
Dr Sondashi urged Government and other stakeholders involved to ensure the formula was not taken away from the hands of Zambians because Zambia stood to benefit a lot from the discovery of an HIV cure.
ZANIS








